Neel Mistry

2 weeks ago | 2minutemedicine.com | Neel Mistry

1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events were similar between both groups. Evidence Rating Level: 1 (Excellent)Study Rundown: Patients with unresectable hepatocellular carcinoma (HCC) face a poor prognosis, and current treatments offer limited long-term benefits. There is a need for more effective first-line therapies in this population.

2 weeks ago | 2minutemedicine.com | Neel Mistry

1. Shoulder dystocia was less common in the early induction group compared to standard care. 2. Serious adverse events were comparable between the two groups. Evidence Rating Level: 1 (Excellent)Study Rundown: Shoulder dystocia is a serious childbirth complication that may be more likely in large for gestational age (LGA) infants. Although early delivery could potentially lower birthweight and reduce complications, it may also introduce other risks.

2 weeks ago | 2minutemedicine.com | Neel Mistry

1. FDC obicetrapib plus ezetimibe significantly decreased LDL cholesterol levels by 48.6% compared to placebo. 2. Serious adverse events were comparable in FDC, obicetrapib, ezetimibe, and placebo groups. Evidence Rating Level: 1 (Excellent)Study Rundown: Lowering LDL cholesterol is a proven strategy to prevent atherosclerotic cardiovascular disease (ASCVD). While current therapies help, many patients remain above target LDL levels or cannot tolerate statins.

1 month ago | 2minutemedicine.com | Neel Mistry

1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events in the semaglutide group compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Peripheral artery disease (PAD) is a serious condition affecting circulation in the legs and is common among individuals with type 2 diabetes. Few therapies are available to improve walking and quality of life for these patients.

1 month ago | 2minutemedicine.com | Neel Mistry

1. Gepotidacin was non-inferior to ceftriaxone plus azithromycin for the primary outcome of microbiological success. 2. There were no serious or treatment-related adverse events in either group. Evidence Rating Level: 1 (Excellent) Study Rundown: Gepotidacin is a new antibacterial agent that may be effective in treating uncomplicated urinary tract infections. Given concerns over antibiotic resistance, alternative treatments for gonorrhea are needed.